Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

Grazoprevir (GZR) plus elbasvir is an approved treatment for chronic infection with hepatitis C virus (HCV) genotype 1 or 4. HCV infection complications include liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The objective of this study was to evaluate the pharmacokinetics an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Antimicrob Agents Chemother
Egile Nagusiak: Caro, Luzelena, Wenning, Larissa, Guo, Zifang, Fraser, Iain P., Fandozzi, Christine, Talaty, Jennifer, Panebianco, Deborah, Ho, Maureen, Uemura, Naoto, Reitmann, Christina, Angus, Peter, Gane, Edward, Marbury, Thomas, Smith, William B., Iwamoto, Marian, Butterton, Joan R., Yeh, Wendy W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology 2017
Gaiak:
Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5700330/
https://ncbi.nlm.nih.gov/pubmed/28947470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00813-17
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak